Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting

Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting

33% ORR and 67% disease control observed with imneskibart triplet in metastatic melanoma following confirmed progression on potent doublet checkpoint inhibitor therapy

Durable responses, Treg reduction and increased CD8/Treg ratio support imneskibart’s differentiated IL-2 mechanism

Well-tolerated outpatient regimen shows no treatment discontinuations due to drug-related adverse events

Phase 2 enrollment ongoing in melanoma and PD-L1+ advanced NSCLC